Showing 3001-3010 of 6035 results for "".
- Hydroxychloroquine Found to Significantly Cut Death Rates in New COVID-19 Studyhttps://modernod.com/news/hydroxychloroquine-found-to-significantly-cut-death-rates-in-new-covid-19-study/2477971/According to a large-scale retrospective analysis published in the International Journal of Infectious Diseases, hydroxychloroquine was associated with a significant decrease in death rate in patients hospitalized with COVID-19, and without heart-related side-effects. Marcus Zervos, division head
- Moderna Reiterates July Start for Phase 3 COVID-19 Vaccine Trial Following Report of Delayhttps://modernod.com/news/moderna-reiterates-july-start-for-phase-3-covid-19-vaccine-trial-following-report-of-delay/2477967/Shares in Moderna fell as much as 9.4% on Thursday after a report indicated that the company’s late-stage trial for potential COVID-19 vaccine mRNA-1273 will be delayed. According to the report in STAT News citing unnamed investigators involved in running the trial, which was slated to begin July
- Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorderhttps://modernod.com/news/massachusetts-eye-and-ear-enters-licensing-agreement-with-biogen-to-develop-treatment-for-inherited-retinal-disorder/2477961/Massachusetts Eye and Ear is entering into an exclusive licensing agreement with Biogen to develop a potential treatment for inherited retinal degeneration due to mutations in the PRPF31 gene, which are among the most common causes for autosomal dominant retinitis pigmentosa. Inhe
- SparingVision Receives European Orphan Designation for its Drug Candidate SPVN06 Dedicated to Inherited Retinal Dystrophieshttps://modernod.com/news/sparingvision-receives-european-orphan-designation-for-its-drug-candidate-spvn06-dedicated-to-inherited-retinal-dystrophies/2477959/SparingVision announced the decision of the European Commission to grant Orphan Drug Designation for SPVN06 for the treatment of inherited retinal dystrophies. The decision is based on a positive opinion from the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP).
- Hospitals in New COVID-19 Hot Spots Face Delicate Balancing Act With Elective Surgerieshttps://modernod.com/news/hospitals-in-new-covid-19-hot-spots-face-delicate-balancing-act-with-elective-surgeries/2477955/Some hospital systems located in states that are seeing huge spikes of COVID-19 are continuing to perform elective procedures and developing strategies to avoid a total shutdown, according to a FierceHealthcare
- Versant Health Debuts New Eye Care Resource Centerhttps://modernod.com/news/versant-health-debuts-new-eye-care-resource-center/2477925/In celebration of Healthy Vision Month this July, Versant Health has launched a new resource center providing tools that enable people to take command of their vision health. Designated by the National Eye Institute, Healthy Vision Month is dedicated to highlighting the importance of eye h
- Study: Dexamethasone Reduces Death In Hospitalized Patients With Severe Respiratory Complications of COVID-19https://modernod.com/news/scientists-hail-dexamethasone-as-major-breakthrough-in-treating-covid-19/2477901/Results of a large trial show that the inexpensive and widely used steroid dexamethasone has the potential to save lives in patients with severe cases of COVID-19. In what some scientists are calling a “major breakthrough” in the coronavirus pandemic, dexamethasone, which is used to reduce
- Aldeyra Therapeutics Receives Orphan Medicinal Product Designation from the European Commission for ADX-2191 Retinal Disease Programhttps://modernod.com/news/aldeyra-therapeutics-receives-orphan-medicinal-product-designation-from-the-european-commission-for-adx-2191-retinal-disease-program/2477898/Aldeyra Therapeutics announced that ADX-2191 has been designated an orphan medicinal product by the European Commission for the treatment of retinal detachment. ADX-2191 is an investigational therapy in clinical development in the U.S. for the prevention of proliferative vitreoretinopathy (PVR),
- Two ARVO Papers Provide New Insights for Contact Lens-Based Myopia Management with Childrenhttps://modernod.com/news/two-arvo-papers-provide-new-insights-for-contact-lens-based-myopia-management-with-children/2477900/Two scientific papers being presented as part of the ARVO (Association for Research in Vision and Ophthalmology) 2020 virtual conference proceedings provide eye care professionals (ECPs) with new insights to aid contact lens-based myopia management with children. ReCSS Study Ex
- Tarsus Pharmaceuticals Announces Positive Results of Phase 2a Study for TP-03 to Treat Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-announces-positive-results-of-phase-2a-study-for-tp-03-to-treat-demodex-blepharitis/2477893/Tarsus Pharmaceuticals announced positive results of its phase 2a Mars Study and the release later this month of the results of a phase 2b randomized controlled study. The Mars study demonstrated that the use of TP-03 for 4 weeks was well-tolerated and showed promising efficacy in the treatment o